High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma

Attal, 1996, A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome, N Engl J Med, 335, 91, 10.1056/NEJM199607113350204 Child, 2003, High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma, N Engl J Med, 348, 1875, 10.1056/NEJMoa022340 Blade, 1996, Treatment of multiple myeloma in elderly people: long-term results in 178 patients, Age Ageing, 25, 357, 10.1093/ageing/25.5.357 Clavio, 1996, Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients, Haematologica, 81, 238 Riccardi, 1998, Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma, Br J Cancer, 77, 485, 10.1038/bjc.1998.77 Corso, 1998, Multiple myeloma in younger patients: the role of age as prognostic factor, Ann Hematol, 76, 67, 10.1007/s002770050365 Quaglino, 1998, Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations. Part IV. Multiple myeloma and Waldenstrom's macroglobulinemia, Aging (Milano), 10, 5 Magagnoli, 2003, Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution, Am J Hematol, 73, 267, 10.1002/ajh.10384 de la Rubia, 2001, Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation, Bone Marrow Transplant, 27, 21, 10.1038/sj.bmt.1702736 Olivieri, 2001, Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience, Bone Marrow Transplant, 27, 1189, 10.1038/sj.bmt.1703034 Palumbo, 2004, Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial, Blood, 104, 3052, 10.1182/blood-2004-02-0408 Blade, 1998, Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant, Br J Haematol, 102, 1115, 10.1046/j.1365-2141.1998.00930.x Sirohi, 2000, The role of autologous transplantation in patients with multiple myeloma aged 65 years and over, Bone Marrow Transplant, 25, 533, 10.1038/sj.bmt.1702188 Mazza, 1999, Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim report, Bone Marrow Transplant, 23, 1273, 10.1038/sj.bmt.1701804 Siegel, 1999, Age is not a prognostic variable with autotransplants for multiple myeloma, Blood, 93, 51, 10.1182/blood.V93.1.51 Badros, 2001, Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years, Br J Haematol, 114, 600, 10.1046/j.1365-2141.2001.02976.x Segeren, 2003, Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study, Blood, 101, 2144, 10.1182/blood-2002-03-0889 Facon, 2006, Superiority of melphalan–prednisolone (MP) and thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma, J Clin Oncol, 24, 1, 10.1200/jco.2006.24.18_suppl.1 Palumbo, 2006, Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial, Lancet, 367, 825, 10.1016/S0140-6736(06)68338-4